

Trendlines Medical Singapore Pte. Ltd. Makes First Investment

Medical start-up, InterVaal Pte. Ltd., addresses catheter-associated urinary tract infection

Misgav, Israel – Singapore – 16 October 2017 - The Trendlines Group Ltd. (“The Trendlines Group”) (SGX: 42T; OTCQX: TRNLY), an Israeli company focused on developing innovation-based medical and agricultural companies, announced that its 76.43% owned subsidiary company, Trendlines Medical Singapore Pte. Ltd. (“Trendlines Medical Singapore”), and its wholly owned subsidiary company, Trendlines Incubators Israel Ltd. (“Trendlines Incubators Israel”) have made an aggregate investment of US\$60,000, (US\$30,000 in cash by Trendlines Medical Singapore and US\$30,000 by sale of intellectual property (“IP”) by Trendlines Incubators Israel) into a medical device start-up company, InterVaal Pte. Ltd. (“InterVaal”), on 29 September 2017. This is the first investment made by Trendlines Medical Singapore.

InterVaal is developing a urological catheter to address the widespread problem of catheter-associated urinary tract infection (CAUTI). CAUTI accounts for 32% of all hospital-associated infections worldwide¹. The Trendlines Group’s in-house innovation unit, Trendlines Labs, will work with InterVaal’s Singapore-based staff to develop the catheter and conduct clinical trials in Singapore.

Eric Loh, CEO of Trendlines Medical Singapore, said, “It is apt that our first investment involves the collaboration of the best minds in Israel and Singapore to develop a new urological catheter targeted to address CAUTI, a global health care concern. The use of urological catheters is projected to increase significantly in Asia, especially driven by our aging population. This novel technology -- invented by Trendlines Labs -- combined with the strong clinical infrastructure of Singapore, makes us confident that InterVaal’s unique CAUTI solution will play a key role in the US\$3 billion urinary catheter market².”

Todd Dollinger, Chairman of Trendlines Medical Singapore and Chairman and CEO of The Trendlines Group, added, “InterVaal is truly a breakthrough development that we expect will substantially reduce catheter-associated urinary tract infections. We are very excited

¹ Centers for Disease Control and Prevention (CDC) www.cdc.gov/hai/

² Transparency Market Research Report, July 2017

that our first Trendlines Medical Singapore investment so perfectly serves our mission of creating and developing companies to improve the human condition. Our InterVaal investment is just the first of what we believe will be many investments in Singapore that will benefit from our business strategy of intense involvement in our portfolio companies. All our companies are housed in our facilities in Israel or Singapore for at least their first two to three years, so our staff can be fully involved in both technology and business development challenges to help bring our companies quickly to market.”

Singapore’s infrastructure is well positioned,” adds Dollinger, “to support the development of novel medical devices that address pervasive problems affecting patients worldwide. Our InterVaal investment brings technology from our in-house Israel-based innovation unit, Trendlines Labs, to our Singapore incubator. Our investment approach is designed to take advantage of technologies from Singapore and the region with the objective to invest in extraordinary innovation-based medical technology solutions that address global unmet clinical needs. We have been successful in doing precisely this in our Israel incubators, and I am confident that Trendlines Medical Singapore will be an important contributor to Singapore, the region, and The Trendlines Group.”

Trendlines Medical Singapore’s investment into InterVaal is not expected to have any material impact on the earnings per share and net tangible asset per share of The Trendlines Group for the financial year ending 31 December 2017.

None of The Trendlines Group’s Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in The Trendlines Group), in the aforementioned.

About Trendlines Medical Singapore Pte. Ltd.

[Trendlines Medical Singapore](#) is a medical technology start-up incubator established by Trendlines and [B. Braun](#), one of the world’s leading medical device companies. Trendlines Medical Singapore discovers, invests in, incubates, and provides broad-ranging support to nurture and develop our Singapore-based novel medical device and companies with a view toward success in the global market.

About Trendlines Labs

[Trendlines Labs](#), the in-house innovation center of The Trendlines Group, partners with global industry leaders and research institutions to create and develop technologies and

products that meet well-defined and substantial unmet market needs. Trendlines Labs co-invests to expand product pipelines and reduce innovation and development risks inherent in product commercialization. The dedicated Trendlines Labs team brings a highly focused approach to innovation and invention. The combination of profound market knowledge and inventive skills creates the ideal environment for shaping ideas into products and improving the human condition.

About The Trendlines Group Ltd.

[Trendlines](#) is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. An intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

Investor Contact Information

Israel

Judith Kleinman, Director

Investor Relations & Corporate Communications judith@trendlines.com

Tel: +972.72.260.7000

Singapore

Reyna MEI

Financial PR reyna@financialpr.com.sg Tel: +65.6438.2990

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).